Abstract

BackgroundNew animal models of chronic pulmonary hypertension in mice are needed. The injection of monocrotaline is an established model of pulmonary hypertension in rats. The aim of this study was to establish a murine model of pulmonary hypertension by injection of the active metabolite, monocrotaline pyrrole.MethodsSurvival studies, computed tomographic scanning, histology, bronchoalveolar lavage were performed, and arterial blood gases and hemodynamics were measured in animals which received an intravenous injection of different doses of monocrotaline pyrrole.ResultsMonocrotaline pyrrole induced pulmonary hypertension in Sprague Dawley rats. When injected into mice, monocrotaline pyrrole induced dose-dependant mortality in C57Bl6/N and BALB/c mice (dose range 6–15 mg/kg bodyweight). At a dose of 10 mg/kg bodyweight, mice developed a typical early-phase acute lung injury, characterized by lung edema, neutrophil influx, hypoxemia and reduced lung compliance. In the late phase, monocrotaline pyrrole injection resulted in limited lung fibrosis and no obvious pulmonary hypertension.ConclusionMonocrotaline and monocrotaline pyrrole pneumotoxicity substantially differs between the animal species.

Highlights

  • New animal models of chronic pulmonary hypertension in mice are needed

  • Analysis of monocrotaline pyrrole (MCTP) and MCTP-injection in rats The chemically-synthesized MCTP was subjected to thin layer chromatography (TLC) to evaluate the efficacy of chemical synthesis and MCTP purity

  • Subcutaneous injection of MCT in Sprague Dawley rats at a dose of 60 mg/kg resulted in dramatic increase in right ventricular systolic pressure (76.87 ± 4.87 versus 25.08 ± 1.35 for control, *p < 0.05) and severe right heart hypertrophy (0.64 ± 0.01 versus 0.30 ± 0.01 for control, *p < 0.05) after four weeks

Read more

Summary

Introduction

New animal models of chronic pulmonary hypertension in mice are needed. The injection of monocrotaline is an established model of pulmonary hypertension in rats. Idiopathic pulmonary arterial hypertension (IPAH) is a severe disease characterized by elevated pulmonary blood pressure and pathological changes in the lung. These changes, such as endothelial injury, and the proliferation and migration of pulmonary vascular smooth muscle (page number not for citation purposes). BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25 cells, lead to a reduction in the lumenal area of pulmonary vessels [1] They are accompanied by right ventricular hypertrophy and end-stage heart failure [2]. This remodeling process is characterized by de novo muscularization of previously non-muscular precapillary vessels, and right heart hypertrophy

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call